AIM ImmunoTech (AIM) Cash from Financing Activities (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Cash from Financing Activities came in at $5.6 million in Q1 2026, up 746.52% YoY from $660000.0 in Q1 2025, and up 105.48% on a QoQ basis from $2.7 million in Q4 2025.
AIM ImmunoTech (AIM) Cash from Financing Activities (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Cash from Financing Activities data on file, last reported at $5.6 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 746.52% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (up 258.25% YoY) and the FY2025 annual result came in at $10.4 million, up 61.2% from the prior year.
- Cash from Financing Activities rose to $5.6 million in Q1 2026, from $2.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $6.7 million in Q3 2025 to a low of $5000.0 in Q2 2023.
- A 5-year average of $1.6 million and a median of $507500.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 48720.0% — and 2025, when it tumbled 85.46%.
- Tracing AIM's Cash from Financing Activities over 5 years: stood at $25000.0 in 2022, then soared by 488.0% to $147000.0 in 2023, then soared by 605.44% to $1.0 million in 2024, then soared by 162.2% to $2.7 million in 2025, then jumped by 105.48% to $5.6 million in 2026.
- The last three Cash from Financing Activities figures came in at $5.6 million (Q1 2026), $2.7 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | 8.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.79 Mn |
| Jun 30, 2026 | 8.79 Mn |
| Mar 31, 2026 | 5.59 Mn |
| Mar 31, 2026 | 5.59 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 6.65 Mn |
| Sep 30, 2025 | 6.65 Mn |
| Jun 30, 2025 | 355,000.00 |
| Jun 30, 2025 | 355,000.00 |
| Mar 31, 2025 | 660,000.00 |
| Mar 31, 2025 | 660,000.00 |
| Dec 31, 2024 | 1.04 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 137,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 2.44 Mn |
| Jun 30, 2024 | 2.44 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.83 Mn |